Hainsworth, John D <br/><br/>
Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium.  [electronic resource] 

 -  Cancer  May 2010 
 - 2448-54 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0008-543X 
<br/><br/><label>Standard No.: </label>10.1002/cncr.25029  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Capecitabine<br/>Deoxycytidine--administration & dosage<br/>Drug Administration Schedule<br/>Drug Resistance, Neoplasm<br/>Female<br/>Fluorouracil--administration & dosage<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoplasms, Unknown Primary--drug therapy<br/>Organoplatinum Compounds--administration & dosage<br/>Oxaliplatin<br/>Recurrence<br/>Retreatment<br/>Salvage Therapy